Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
Reuben Benjamin(King's College London), Jackie Chappell, Danielle Pinner(Great Ormond Street Hospital), Jen Lewis, Maria Almena-Carrasco(Servier (France)), Laarni Bonganay, Mohamad Mohty(Sorbonne Université), Nitin Jain(Parul University), Marcela V. Maus(Center for Cancer Research), Victoria Potter(King's College Hospital NHS Foundation Trust), Cyril Konto(World Trade Organization), Sandra Dupouy(Servier (France)), Anne Philippe(Pfizer (France)), E. W. Prosser Thomas(Servier (France)), Svetlana Balandraud(Enterome (France)), Victoria Metaxa, Waseem Qasim(University College London), Piers Patten, Kirsty Cuthill, Andrea Kühnl(King's College Hospital), Rose Ellard, Deborah Yallop(King's College Hospital NHS Foundation Trust), Farzin Farzaneh, Agnieszka Jóźwik(King's College Hospital NHS Foundation Trust), Sylvain Fouliard(Servier (France)), Paul Veys(Great Ormond Street Hospital), Fabien Vitry(Servier (France)), Athos Gianella-Borradori(Servier (France)), Matthew J. Frigault(Harvard University), Oana Mirci‐Danicar(Great Ormond Street Hospital), Florence Binlich(Servier (France)), Nicolas Boissel(Inserm), Sylvain Arnould(Servier (France)), Antonio Pagliuca, Charlotte Graham(Broad Institute), Stephen Devereux, Giovanna Lucchini(Great Ormond Street Hospital), Shireen Kassam, Nicolas Ferry(Servier (France)), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), André Baruchel(Hôpital Robert-Debré), Majid Kazmi, Orla Stewart, Lorraine Catt, Ghulam Mufti, Ibtissam Marchiq(AVL (France))
Cited by 358
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k